Loading…
Mesoblast Limited is projected to rise to $18.61 by 2027, a +21% move from its current price of $15.44. MESO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $15.01 | $15.45 | $15.90 | +0.06% |
| Jul 13 | $14.84 | $15.46 | $16.10 | +0.13% |
| Jul 14 | $14.71 | $15.47 | $16.26 | +0.19% |
| Jul 15 | $14.61 | $15.48 | $16.40 | +0.26% |
| Jul 16 | $14.52 | $15.49 | $16.52 | +0.32% |
| Jul 17 | $14.44 | $15.50 | $16.64 | +0.39% |
| Jul 18 | $14.37 | $15.51 | $16.74 | +0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.37 | $15.51 | $16.74 | +0.45% |
| Week 2 | $13.98 | $15.58 | $17.36 | +0.90% |
| Week 3 | $13.71 | $15.65 | $17.87 | +1.36% |
| Week 4 | $13.49 | $15.72 | $18.32 | +1.81% |
| Week 5 | $13.31 | $15.79 | $18.74 | +2.27% |
| Week 6 | $13.15 | $15.86 | $19.13 | +2.73% |
| Week 7 | $13.01 | $15.93 | $19.51 | +3.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Mesoblast Limited is a healthcare company that develops regenerative medicine products through its subsidiaries. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company operates in Australia, the United States, Singapore, and Switzerland.
Incorporated in 2004 and headquartered in Melbourne, Australia, Mesoblast offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft-versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn’s disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis and diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co.
Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain.
MESO is currently priced at $15.44 per share, with a market cap of $2B and a rank of 2029. The near-term outlook shows a 2026 price forecast with a min of $13.19, an average of $15.44, and a max of $21.90, with an ROI of 0 and a neutral sentiment.
The forecast extends into 2027 with an average of $18.61 and a 20.5% ROI, followed by 2028 with an average of $19.87 and a 28.7% ROI, and 2029 with an average of $22.29 and a 44.4% ROI, all marked bullish sentiment. By 2030 the average rises to $23.65 (53.2% ROI), and the trajectory continues upward toward 2040 and 2050, with 2040 averaging $68.90 (346.3% ROI) and 2050 averaging $155.76 (908.8% ROI), all with a bullish sentiment.
A major floor 19.9% below — a decisive break under it would weaken the trend.
The nearest floor, 14.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.7% away) — a breakout level to watch.
A major ceiling 10.7% above — clearing it would confirm fresh momentum.
Key MESO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MESO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.74 | Buy | $14.85 | Buy |
| MA 10 | $14.25 | Buy | $14.60 | Buy |
| MA 20 | $14.37 | Buy | $14.49 | Buy |
| MA 50 | $14.67 | Buy | $14.67 | Buy |
| MA 100 | $15.02 | Buy | $15.09 | Buy |
| MA 200 | $16.19 | Sell | $15.23 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.63 | Neutral |
| Stoch RSI (14) | 96.79 | Sell |
| CCI (20) | 131.23 | Buy |
| Williams %R (14) | -4.66 | Info |
| MACD (12,26,9) | 0.14 | Buy |
| ROC (12) | 0.39 | Buy |
| Bollinger %B (20,2) | 0.90 | Neutral |
| Stochastic %K (14) | 95.34 | Sell |
| TRIX (15) | -0.09 | Sell |
| Awesome (5,34) | 0.27 | Buy |
| Ultimate (7,14,28) | 78.54 | Sell |
| Momentum (10) | 0.94 | Buy |
| Aroon Osc (25) | -8.00 | Sell |
| Hull MA (9) | 15.14 | Buy |
| ADX (14) | 11.09 | Neutral |
| ATR (14) | 0.37 | Info |
The 30-day picture shows a bullish tilt with RSI(14) at 60. The price is above the SMA50 at $14.67 and below the SMA200 at $16.19, indicating a mixed short-term dynamic.
Key support is at $13.19 and resistance at $15.55, framing a near-term range. The 30-day trading range spans from $12.76 to $18.68, and annualized volatility sits at 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.19 | $15.44 | $21.90 | 0% | Neutral | |
| $14.73 | $18.61 | $24.92 | +21% | Bullish | |
| $15.27 | $19.87 | $27.65 | +29% | Bullish | |
| $16.72 | $22.29 | $31.99 | +44% | Bullish | |
| $17.35 | $23.65 | $34.81 | +53% | Bullish | |
| $22.32 | $31.03 | $46.69 | +101% | Bullish | |
| $26.02 | $36.86 | $56.58 | +139% | Bullish | |
| $25.78 | $37.15 | $58.07 | +141% | Bullish | |
| $27.97 | $40.99 | $65.13 | +165% | Bullish | |
| $28.92 | $43.06 | $69.47 | +179% | Bullish | |
| $43.05 | $68.90 | $118.55 | +346% | Bullish | |
| $85.84 | $155.76 | $294.21 | +909% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $13.19 | $15.44 | $18.54 | +0.00% |
| August 2026 | $13.62 | $16.10 | $19.57 | +4.30% |
| September 2026 | $13.74 | $16.37 | $20.13 | +1.65% |
| October 2026 | $13.51 | $16.20 | $20.12 | -1.05% |
| November 2026 | $13.77 | $16.60 | $20.78 | +2.45% |
| December 2026 | $14.33 | $17.36 | $21.90 | +4.61% |
Click any year to see its month-by-month MESO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Mesoblast Limited's 2026 outlook centres on $15.44, within a $13.19 to $21.90 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, MESO could reach as high as $24.92, with a base case around $18.61 and support toward $14.73 — roughly +21% from $15.44. Momentum favours further upside here.
Expect MESO to range from $15.27 to $27.65 through 2028. The $19.87 average target implies a +29% move from current prices. That is up +7% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The MESO price prediction for 2029 points to an average of $22.29 (low $16.72, high $31.99) — a potential gain of +44% on today's $15.44. Momentum favours further upside here.
In 2030, MESO is projected to trade between $17.35 and $34.81, averaging $23.65 — a potential gain of +53% from today's $15.44. That is up +6% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Mesoblast Limited's 2031 outlook centres on $31.03, within a $22.32 to $46.69 range. That is up +31% on the projected 2030 average. That marks a +101% change versus current levels. Momentum favours further upside here.
By 2032, MESO could reach as high as $56.58, with a base case around $36.86 and support toward $26.02 — roughly +139% from $15.44. Buyers look set to stay in control over this stretch.
Expect MESO to range from $25.78 to $58.07 through 2033. The $37.15 average target implies a +141% move from current prices. That is up +1% on the projected 2032 average. Momentum favours further upside here.
The MESO price prediction for 2034 points to an average of $40.99 (low $27.97, high $65.13) — a potential gain of +165% on today's $15.44. Buyers look set to stay in control over this stretch.
In 2035, MESO is projected to trade between $28.92 and $69.47, averaging $43.06 — a potential gain of +179% from today's $15.44. That is up +5% on the projected 2034 average. Momentum favours further upside here.
Mesoblast Limited's 2040 outlook centres on $68.90, within a $43.05 to $118.55 range. That is up +60% on the projected 2035 average. That marks a +346% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, MESO could reach as high as $294.21, with a base case around $155.76 and support toward $85.84 — roughly +909% from $15.44. Momentum favours further upside here.
Investing $1,000 in MESO today (≈ 64.766839 MESO) could be worth
$10,088.08
+$9,088.08 (+909%) by 2050 · US Dollar
Based on the average projected MESO price of $155.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MESOwould be worth at today's price.
$1,000 invested in MESO on Jul 10, 2025 (≈ 90.744098 MESO) would be worth
$1,401.09
+$401.09 (+40.1%) today · 1.40× · US Dollar
Based on a MESO entry price of $11.02 vs. today's $15.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.38 | $1,073.71 | +7.4% |
| 1 month ago | $13.8 | $1,118.84 | +11.9% |
| 3 months ago | $15 | $1,029.33 | +2.9% |
| 6 months ago | $18.67 | $827 | -17.3% |
| 1 year ago | $11.02 | $1,401.09 | +40.1% |
| All time (5.0y) ago | $15.6 | $989.74 | -1.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MESO forecast.
Our base-case forecast reaches $31.00 around 2031.
Implied market cap at $31.00: $4.01B
The multi-year outlook is bullish, with the average price rising from $23.65 in 2030 to $155.76 in 2050 and a corresponding rise in estimated ROI from 53.2% to 908.8%. The forecast also shows substantial upside in earlier years, including 2031 (avg $31.03, ROI 101%), 2032 (avg $36.86, ROI 138.7%), and 2033 (avg $37.15, ROI 140.6%). By 2040, the average reaches $68.90 with a 346.3% ROI, and by 2050 the average is $155.76 with an ROI of 908.8%, all with bullish sentiment.
These figures are estimates and not guaranteed, and actual results may differ.
Tap a question to reveal the answer.
The forecast shows a min of $17.35, an avg of $23.65, and a max of $34.81, with an ROI of 53.2% and a bullish sentiment.
The outlook presents bullish sentiment across multiple years with rising averages and ROIs up to 908.8% by 2050. These are estimates, not guarantees.
Yes. The 2040 max is $118.55 and the 2050 max is $294.21, so crossing $100 is anticipated within the forecast window.
Current price is $15.44 and market cap is $2B; the rank is 2029.
The 30-day range is $12.76 to $18.68 and annualized volatility is 60%.
Mesoblast Limited Community Discussion
0Share your Mesoblast Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.